QUE Oncology, Inc. (QUE) was formed through a collaboration between Emory University, in Atlanta, Georgia, and The University of Queensland (UQ) research commercialization company, UniQuest, in Brisbane, Australia. QUE licenses intellectual property originating from research discoveries at both UQ and Emory’s Institute for Drug Development (EIDD). The leading drug candidate is Q-122, a compound with anti-inflammatory properties that is in Phase 1b clinical development for the treatment of hot flashes in women with breast cancer who are receiving anti-estrogen therapy. Additional cancer research projects that have been identified to supply the QUE Oncology pipeline are designed to address prostate cancer, breast cancer, melanoma, and cancer pain.